Home › NDC Lookup › Ingredients › Ciprofloxacin Hydrochloride › 72888-0102-23
CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL Solution, 10 mL Bottle — NDC 72888-0102-23 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 72888-0102-23: CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL Solution, 10 mL Bottle

by Advagen Pharma Limited

This is a package of 10 mL of CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL Solution from Advagen Pharma Limited, first listed with the FDA Mar 2022 and currently FDA-listed; retail pharmacies pay about $0.8545 per mL (NADAC).

🏷️ FDA NDC (as labeled) 72888-102-23 billing pads the product segment with a zero
This package
Contains10 mL Cost per mL$0.8545 NADAC Per package$8.55 / 10 ml Pack sizes3 compare ↓
Also priced by: Part D plans $2.57/unit — full pricing hub ↓
Rx only Generic FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 5, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 72888-102-23 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
72888 labeler · 102 product · 23 package
Package marketed since
Mar 16, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
10 mL per package
Barcode (UPC)
0372888102214, 0372888102238, 0372888102221
FDA record last changed
Nov 5, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 72888-102-23
Product NDC 72888-102
11-digit billing NDC 72888010223
NCPDP billing unit ML — per mL (volume)
RxCUI 309307
UNII 4BA73M5E37
UPC 0372888102214, 0372888102238, 0372888102221
Application # ANDA075928
SPL Set ID 74af98f1-eb6d-473b-94a9-67920dba8c3d
Established class (EPC) Fluoroquinolone Antibacterial
Mechanism of action Cytochrome P450 1A2 Inhibitors
Chemical class Fluoroquinolones
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2022-03-16
Route OPHTHALMIC
Dosage form SOLUTION
Substance CIPROFLOXACIN HYDROCHLORIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86101023102010
GCN Seq No 015861
GCN 33580
HICL code 004124
Ingredient (HICL) Ciprofloxacin Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.18.00
AHFS class Quinolone Antibiotics
FDB label name CIPROFLOXACIN 0.3% EYE DROP
FDB brand name Ciprofloxacin Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 015861
  • GCN: 33580
  • GPI-14 (Medi-Span): 86101023102010
  • HICL (First Databank): 004124
  • AHFS class code: 08:12.18.00
  • RxCUI (RxNorm): 309307
Why two NDCs? The FDA registers this code as 72888-102-23 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72888-0102-23. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Fluoroquinolone Antibacterial class.

Pharmacologic class Fluoroquinolone Antibacterial
Drug family (ATC) Fluoroquinolones, Fluoroquinolones, Antiinfectives
How it works Cytochrome P450 1A2 Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CIPROFLOXACIN 0.3% EYE DROP Ingredient Ciprofloxacin Hcl
📖 What it is MedlinePlus · NLM

Ciprofloxacin ophthalmic solution is used to treat bacterial infections of the eye including conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeball and the inside of the eyelid) and corneal ulcers (infection and loss of tissue in the clear front part of the eye). Ciprofloxacin ophthalmic ointment is used to treat conjunctivitis. Ciprofloxacin is in a class of antibiotics called fluoroquinolones. It works by killing the bacteria that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats bacterial infections such as urinary tract, respiratory, skin, bone and abdominal infections, depending on the form. Eye and ear versions treat eye and ear infections. It...
  • Swallow them as prescribed, usually every 12 hours, and finish the full course unless your doctor says otherwise. Keep them 2 hours before or 6 hours after antacids, multivitamins,...
  • How should I take my ciprofloxacin tablets?
  • The most common ones are nausea, diarrhea, vomiting, rash and abnormal liver tests. Most are mild, but tell your doctor if they bother you.
📖 Read our full Ciprofloxacin guide →
11
Nutrient depletion considerations

Ciprofloxacin may be associated with lower levels of 11 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.855 $8.55 / 10 ml
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $2.57 $25.73 / 10 ml
NADAC price history (per mL) — tap or hover for the price & month
Aug 2025 Jan 2026 Jun 2026 Nov 2026 $1.274 $0.796
▼ Down 30% over the last 16 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
72888-0102-21 72888-102-21 Main listing 2.5 mL in 1 BOTTLE $2.63 / mL $6.58 2022-03-16 — Active
72888-0102-22 72888-102-22 5 mL in 1 BOTTLE $1.43 / mL $7.16 2022-03-16 — Active
72888-0102-23 You're viewing this 10 mL in 1 BOTTLE $0.8545 / mL $8.55 2022-03-16 — Active

This pack has the lowest per-mL cost of the 3 priced pack sizes ($0.8545 NADAC).

Pack size FAQ

What quantity is in this package?
This package contains 10 mL — 10 ml in 1 bottle.
How does this package differ from NDC 72888-0102-21?
Both are CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL Solution — the drug itself is identical. This page's package is the 10 mL one, while NDC 72888-0102-21 is the 2.5 ml package. Per-mL NADAC also differs: $0.8545 here vs $2.63 for the 2.5 ml pack.
What NDC number is used to bill for this package of CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ciprofloxacin Hydrochloride 3 mg/mLthis 72888-0102-23 Advagen 10 ml $0.855 AT Availability likely —
Ciprofloxacin Hydrochloride 3 mg/mL 61314-0656-05 Sandoz 1 bottle $1.433 AT Availability likely +68%
ciprofloxacin 3 mg/mL 69315-0308-02 Leading 1 bottle $2.631 AT Availability likely +208%
Ciprofloxacin Hydrochloride 3 mg/mL 50090-0882-00 A-S 1 bottle — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 50090-1754-00 A-S 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 50090-4217-00 A-S 1 bottle — AT FDA listed —
Ciprofloxacin HCl Ophthalmic 3 mg/mL 59390-0217-02 Altaire 2.5 ml — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 63187-0985-05 Proficient 1 bottle — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 67296-0142-01 Redpharm 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 67296-1703-09 Redpharm 2 bottles — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 68071-3351-03 NuCare 10 ml — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 68071-4139-05 NuCare 5 ml — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 68071-4235-03 NuCare 2.5 ml — AT FDA listed —
ciprofloxacin 3 mg/mL 68071-4672-03 NuCare 2.5 ml — AT FDA listed —
ciprofloxacin 3 mg/mL 68071-4679-05 NuCare 5 ml — AT FDA listed —
ciprofloxacin 3 mg/mL 68788-7500-05 Preferred 1 bottle — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 68788-8198-05 Preferred 1 bottle — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 70518-1170-00 REMEDYREPACK 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 71205-0300-05 Proficient 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 76420-0588-02 Asclemed 1 bottle — AT FDA listed —
Ciprofloxacin Hydrochloride 3 mg/mL 76420-0942-03 Asclemed 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 80425-0499-01 Advanced 1 bottle — AT FDA listed —
ciprofloxacin 3 mg/mL 85766-0023-05 Sportpharm 1 bottle — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
Listed with the FDA since
Mar 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Ciprofloxacin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII Q40Q9N063P
    Acetic acid is a weak organic acid commonly used in medicines as a buffer and pH adjuster. It helps maintain the proper acidity level to ensure the drug remains stable and effective in its formulation.
  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 3OWL53L36A
    A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
  • UNII 4550K0SC9B
    Sodium acetate is a salt derived from acetic acid. It acts as a buffer to help maintain the medicine's pH stability and may serve as a preservative or solubilizer in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAdvagen Pharma Limited
Application holderRUBICON RESEARCH LTD
FDA applicationANDA075928 (ANDA)
Labeler code72888
First marketedMar 2022
Product typeHuman Prescription Drug
Portfolio79 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 63 words ▾

INDICATIONS AND USAGE: Ciprofloxacin ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.

⏱️ Dosage and Administration 135 words ▾

DOSAGE AND ADMINISTRATION: Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.

Treatment may be continued after 14 days if corneal re-epithelialization has not occurred. Bacterial Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.

⛔ Contraindications 34 words ▾

CONTRAINDICATIONS: A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

⚠️ Warnings 89 words ▾

WARNINGS: NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria,and itching.

Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. Remove contact lenses before using.

🤒 Adverse Reactions 107 words ▾

ADVERSE REACTIONS: The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (SEE PRECAUTIONS ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation.

Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision. To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🆘 Overdosage 18 words ▾

OVERDOSAGE: A topical overdose of ciprofloxacin ophthalmic solution may be flushed from the eye(s) with warm tap water.

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY: Systemic Absorption: A systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL. The mean concentration was usually less than 2.5 ng/mL.

Microbiology : Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram- positive organisms. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA. Ciprofloxacin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections (SEE INDICATIONS AND USAGE section): Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) Gram-Negative: Haemophilus influenzae Pseudomonas aeruginosa Serratia marcescens Ciprofloxacin has been shown to be active in vitro against most strains of the following organisms, however, the clinical significance of these data is unknown: Gram-Positive: Enterococcus faecalis (Many strains are only moderately susceptible) Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus saprophyticus Streptococcus pyogenes Gram-Negative: Acinetobacter calcoaceticus Escherichia coli Proteus mirabilis subsp. anitratus Haemophilus ducreyi Proteus vulgaris Aeromonas caviae Haemophilus parainfluenzae Providencia rettgeri Aeromonas hydrophila Kiebsiella pneumoniae Providencia stuartii Brucella melitensis Klebsiella oxytoca Salmonella enteritidis Campylobacter coli Legionella pneumophila Salmonella typhi Campylobacter jejuni Moraxella (Branhamella) Shigella sonneii Citrobacter diversus catarrhalis Shigella flexneri Citrobacter freundii Morganella morganii Vibrio cholerae Edwardsiella tarda Neisseria gonorrhoeae Vibrio parahaemolyticus Enterobacter aerogenes Neisseria meningitidis Vibrio vulnificus Enterobacter cloacae Pasteurella multocida Yersinia enterocolitica Other Organisms: Chlamydia trachomatis (only moderately susceptible) and Mycobacterium tuberculosis (only moderately susceptible).

Most strains of Pseudomonas cepacia and some strains of Pseudomonas maltophilia are resistant to ciprofloxacin as are most anaerobic bacteria, including Bacteroides fragilis and Clostridium difficile . The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin in vitro usually develops slowly (multiple-step mutation).

Ciprofloxacin does not cross-react with other antimicrobial agents such as beta-lactams or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. Clinical Studies: Following therapy with ciprofloxacin ophthalmic solution, 76% of the patients with corneal ulcers and positive bacterial cultures were clinically cured and complete re-epithelialization occurred in about 92% of the ulcers. In 3 and 7 day multicenter clinical trials, 52% of the patients with conjunctivitis and positive conjunctival cultures were clinically cured and 70-80% had all causative pathogens eradicated by the end of treatment.

In a randomized, double-masked, multicenter, parallel-group clinical trial of pediatric patients with bacterial conjunctivitis, between birth and 31 days of age, patients were dosed with ciprofloxacin or another anti-infective agent. Clinical outcomes for the trial demonstrated a clinical cure rate of 80% at Day 9 anda microbiological eradication success rate of 85% at Day 9. Please note that microbiologic eradication does not always correlate with clinical outcome in anti- infective trials.

📦 How Supplied / Storage and Handling 104 words ▾

How Supplied: As a sterile ophthalmic solution: 2.5 mL, 5 mL and 10 mL in translucent LDPE bottle, translucent LDPE nozzle and tan coloured polypropylene closure. 2.5 mL - NDC 72888-102-21 5 mL - NDC 72888-102-22 10 mL - NDC 72888-102-23 STORAGE: Store at 2°C to 25°C (36°F to 77°F). Protect from light.

ANIMAL PHARMACOLOGY: Ciprofloxacin and related drugs have been shown to cause arthropathy in immature animals of most species tested following oral administration. However, a one-month topical ocular study using immature Beagle dogs did not demonstrate any articular lesions. Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520, USA.

Rev. 01, 09/2024

📋 Description 167 words ▾

DESCRIPTION: Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.

It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C 17 H 18 FN 3 O 3 •HCL•H 2 O and its chemical structure is as follows: Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. Each mL of ciprofloxacin ophthalmic solution contains: Active: Ciprofloxacin hydrochloride 3.5 mg equivalent to 3mg base.

Preservative: Benzalkonium chloride 0.006%. Inactives: Acetic acid, edetate disodium 0.05%, mannitol 4.6%, Sodium acetate, hydrochloric acid and/or sodium hydroxide (to adjust pH) and water for injection. The pH is between 3.5 to 5.5 and the osmolality is between 290 to 300 mOsms/kg.

Ciprofloxacin Structure

⚠️ Precautions ~3 min read ▾

PRECAUTIONS: General: As with other antibacterial preparations, prolonged use of ciprofloxacin may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. In clinical studies of patients with bacterial corneal ulcer, a white crystalline precipitate located in the superficial portion of the corneal defect was observed in 35 (16.6%) of 210 patients. The onset of the precipitate was within 24 hours to 7 days after starting therapy.

In one patient, the precipitate was immediately irrigated out upon its appearance. In 17 patients, resolution of the precipitate was seen in 1 to8 days (seven within the first 24 to 72 hours), in five patients, resolution was noted in 10 to 13 days. In nine patients, exact resolution days were unavailable; however, at follow-up examinations, 18 to 44 days after onset of the event, complete resolution of the precipitate was noted.

In three patients, outcome information was unavailable. The precipitate did not preclude continued use of ciprofloxacin, nor did it adversely affect the clinical course of the ulcer or visual outcome. (SEE ADVERSE REACTIONS ).

Information for patients: Do not touch dropper tip to any surface, as this may contaminate the solution. Drug Interactions: Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Eight in vitro mutagenicity tests have been conducted with ciprofloxacin and the test results are listed below: Salmonella /Microsome Test (Negative) E. coli DNA Repair Assay (Negative) Mouse Lymphoma Cell Forward Mutation Assay (Positive) Chinese Hamster V79 Cell HGPRT Test (Negative) Syrian Hamster Embryo Cell Transformation Assay (Negative) Saccharomyces cerevisiae Point Mutation Assay (Negative) Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative) Rat Hepatocyte DNA Repair Assay (Positive) Thus, two of the eight tests were positive, but the results of the following three in vivo test systems gave negative results: Rat Hepatocyte DNA Repair Assay Micronucleus Test (Mice) Dominant Lethal Test (Mice) Long term carcinogenicity studies in mice and rats have been completed.

After daily oral dosing for up to two years, there is no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species. Pregnancy: Reproduction studies have been performed in rats and mice at doses up to six times the usual daily human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ciprofloxacin. In rabbits, as with most antimicrobial agents, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion.

No teratogenicity was observed at either dose. After intravenous administration, at doses up to 20 mg/kg, no maternal toxicity was produced and no embryotoxicity or teratogenicity was observed. There are no adequate and well controlled studies in pregnant women.

Ciprofloxacin Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: It is not known whether topically applied ciprofloxacin is excreted in human milk; however, it is kno… [Excerpted — this section continues on DailyMed.]

🔬 Clinical Studies 136 words ▾

Clinical Studies: Following therapy with ciprofloxacin ophthalmic solution, 76% of the patients with corneal ulcers and positive bacterial cultures were clinically cured and complete re-epithelialization occurred in about 92% of the ulcers. In 3 and 7 day multicenter clinical trials, 52% of the patients with conjunctivitis and positive conjunctival cultures were clinically cured and 70-80% had all causative pathogens eradicated by the end of treatment. In a randomized, double-masked, multicenter, parallel-group clinical trial of pediatric patients with bacterial conjunctivitis, between birth and 31 days of age, patients were dosed with ciprofloxacin or another anti-infective agent.

Clinical outcomes for the trial demonstrated a clinical cure rate of 80% at Day 9 anda microbiological eradication success rate of 85% at Day 9. Please note that microbiologic eradication does not always correlate with clinical outcome in anti- infective trials.

📄 Package Label / Principal Display Panel 136 words ▾

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Container Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Container Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Container Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-21 - 2.5 mL Container Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-22 - 5 mL Container Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Carton Ciprofloxacin Ophthalmic Solution, 0.3% - NDC 72888-102-23 - 10 mL Container

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Ciprofloxacin Hydrochloride — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity6,225
Pain6,159
Fatigue6,088
Nausea5,906
Diarrhoea5,882
Arthralgia5,592
Acute Kidney Injury4,768

Age at onset

Neonate88
Infant103
Child323
Adolescent288
Adult8,813
Elderly5,555

Reporter sex

96,911 reports
Male · 42%
Female · 58%
Unknown · 0%

Serious outcomes

Hospitalization37,639
Death9,732
Disabling6,974
Life-threatening5,881
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 9,981 2,021
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.